Navigation Links
Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma

- 100 percent of patients treated with VELCADE, cyclophosphamide, and prednisone alive at one year -

KOS, Greece, June 28, 2007 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today reported on the presentation of results from clinical trials of VELCADE based therapies that showed high complete remission / complete response(1) (CR) rates in previously treated multiple myeloma (MM) patients. These findings were presented at the prestigious 11th International Myeloma Workshop (IMW) in Kos, Greece. Highlights included:

    


    -- VELCADE, cyclophosphamide and prednisone (VCP) demonstrated an overall

       response rate (ORR) of 93 percent including a CR(1) rate of 54 percent.

       At one year, 100 percent of patients were alive.

    -- VELCADE, lenalidomide and dexamethasone (VRD) showed an ORR of 68

       percent with a 5 percent CR(1) rate in a pilot study of heavily

       pretreated patients, including those who had been previously treated

       with VELCADE or lenalidomide.

"By combining the power of VELCADE with other active agents, we are seeing some of the strongest reported efficacy in previously treated multiple myeloma patients," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "The wealth of combination data that are being generated promises to strengthen the U.S. market-leading role of VELCADE."

Weekly VELCADE, Cyclophosphamide and Prednisone in Myeloma (Abstract #PO- 639)

"VELCADE has shown synergistic activity with alkylating agents by generating substantially high and durable complete remission rates," said Donna Reece, M.D., Princess Margaret Hospital. "This is an important finding for the field of multiple myeloma and leads us to believe that the combination of VELCADE and cyclophosphamide warrants further investigation in the front-line setting with the goal of prolonging patients' survival."

The Phase II study was d
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:10/30/2014)... Oct. 30, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... and technology platform company serving the pharmaceutical, biotechnology, and ... and the United States ... in the Tel Aviv area ... promote WuXi,s broad platform of integrated R&D services to ...
(Date:10/30/2014)... -- The number of retail health clinics in ... to drug store chains, according to Kalorama Information.  In ... retail clinic growth had been at a standstill, but ... of retail clinics reached nearly 1,600 according to the ... and 2014 Consumer Survey Results .  More ...
(Date:10/30/2014)... BOTHELL, Wash. , Oct. 30, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... Company,s third quarter 2014 financial results will be released ... will host a conference call and live webcast at ...
Breaking Medicine Technology:WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... Genmab A/S (CSE: GEN),announced today that the results ... patients with rheumatoid,arthritis (RA) have been accepted for ... Rheumatology (EULAR). The oral,presentation, which will include new ... with ofatumumab, along with data,from the previous interim ...
... Study Shows At Least 10 Genetic Variants Are ... 26, 2007 – In the most,comprehensive look at ... a U.S.-Finnish team, working in close collaboration with ... genetic variants,associated with increased risk of diabetes and ...
Cached Medicine Technology:Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 2Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 3Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 4Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 5Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 6Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 7
(Date:10/30/2014)... Don Allred Insurance, a leading provider of ... North Carolina residents, is excited to announce the Grand ... Mall. The new branch has been up and running ... all facets of the insurance selection process from quote ... Allred couldn’t be happier with the timing of this ...
(Date:10/30/2014)... Five months after their expansion, the ... announces new branding and a website to accompany their ... David Mepham’s promotion to name partner earlier this year, ... include Mepham’s name and better reflect their combined litigation ... the decision to implement new branding reflects Hodgkinson Street ...
(Date:10/30/2014)... 2014 Paramount Rx, a full-service prescription ... efforts to help people save money through its innovative ... for prescription drugs in the new health care system, ... to bridge the relationship between consumers, businesses and the ... challenges people face today with medical costs is the ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. ... with prostate cancer who also have certain heart problems may ... new study suggests. , , The therapy in question is called ... reduce levels of male hormones to prevent the growth of ... research, this hormone therapy was linked to triple the risk ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... Ebola outbreak in Liberia -- one of three West African ... Health Organization officials said Wednesday. Dr. Bruce Aylward, WHO,s ... number of burials in Liberia and no increase in laboratory-confirmed ... push to tame the epidemic may be making some progress, ...
Breaking Medicine News(10 mins):Health News:Allred Insurance Satellite Office Grand Opening 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3
... better known for their close association to fishes has ... ,Dietary intake of omega 3 fatty acids such ... may curb the growth of breast cancer cells, ... of Cancer., ,Min Wu and colleagues at Methodist ...
... study in USA to see if the procedures of ... ,The study will enroll of more than 16,000 ... be safely performed in smaller, community hospitals, easing access ... the first study patients in early fall 2005. ...
... cancer remain the most feared diseases all around the ... inhaler, potentially offering adult diabetics an alternative to injections// ... to be approved by the FDA. ,If approved, ... to the insulin injections taken by millions worldwide. The ...
... people may accelerate the heart conditions by releasing the levels ... of 32 people with heart failure, the 14 patients who ... this protein in their blood. ,The protein, tumor necrosis ... of proteins called cytokines, chemical messengers that are mobilized when ...
... Research suggests that 25% of the MRSA infections in the ... the hospital. The research was published in the latest ... many sites; one serious form of infection is that in ... scheme counts MRSA bacteremia by hospital trust, but it has ...
... doctors of American Origin are helping out the victims from ... members of the American Association of Physicians of Indian Origin// ... US who number over 25,000 - have volunteered their services ... Mississippi and Alabama. ,The volunteers hail from almost all ...
Cached Medicine News:Health News:Exubera could mean the end of an insulin injection era for diabetics 2Health News:Indian doctors in America help Katrina victims 2
... from the latest 60 series bronchoscopes., ... range, focussing on providing clinicians with ... Olympus has a impressive range of ... in the respiratory tract to meet ...
Fujinon's standard fiberoptic bronchoscope is fully submersible and offers a large image for more comfortable and efficient observation....
... performance fiberoptic imaging from the latest ... improved its fiberscope range, focussing on ... enhanced image performance. Olympus has a ... diagnosis and therapy in the respiratory ...
... The BF-1T40 has been designed with a ... in therapeutic applications. This permits the selection ... those for electrosurgical procedures. In addition, this ... field of view and a bright, high-resolution ...
Medicine Products: